JP2002509529A - Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 - Google Patents
Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法Info
- Publication number
- JP2002509529A JP2002509529A JP52589298A JP52589298A JP2002509529A JP 2002509529 A JP2002509529 A JP 2002509529A JP 52589298 A JP52589298 A JP 52589298A JP 52589298 A JP52589298 A JP 52589298A JP 2002509529 A JP2002509529 A JP 2002509529A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- methotrexate
- treatment
- inhibitor
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.IL-1インヒビターおよび少なくとも1つのさらなる抗炎症性化合物を含む 、薬学的組成物。 2.前記抗炎症性化合物がメトトレキセート(N-[4-[(2,4-ジアミノ-6-プテリ ジニル)メチルアミノ]ベンゾイル]-L-グルタミン酸)である、請求項1に記載の 薬学的組成物。 3.前記IL-1インヒビターがIL-1レセプターアンタゴニストである、請求項1 に記載の薬学的組成物。 4.前記IL-1レセプターアンタゴニストが、IL-1raα、IL-1raβ、およびIL-1 raxからなる群からの少なくとも1つの化合物を含む、請求項3に記載の薬学的 組成物。 5.前記IL-1レセプターアンタゴニストが、ヒトの組換えIL-1raである、請求 項4に記載の薬学的組成物。 6.前記ヒトの組換えIL-1raが約200mgまでの量で存在する、請求項5に記載 の薬学的組成物。 7.前記メトトレキセートが約25mgまでの量で存在する、請求項2に記載の薬 学的組成物。 8.IL-1インヒビターの投与と組合せた、哺乳動物の急性または慢性の疾患を 処置するための薬物の調製における、IL-1インヒビター以外の抗炎症性化合物の 使用。 9.前記抗炎症性化合物がメトトレキセートである、請求項8に記載の使用。 10.前記薬物における前記メトトレキ七ートの量が、約25mgまでである、請 求項9に記載の使用。 11.前記メトトレキセートが経口投与される、請求項8〜10に記載の使用 。 12.さらなる抗炎症性化合物の投与と組み合わせた、哺乳動物で急性または 慢性炎症性疾患を処置するための薬物の調製における、IL-1インヒビターの使用 。 13.前記抗炎症性化合物がメトトレキセートである、請求項12に記載の使 用。 14.前記IL-1インヒビターがIL-1レセプターアンタゴニストである、請求項 12に記載の使用。 15.前記IL-1レセプターアンタゴニストが、IL-1raα、IL-1raβ、およびIL -1raxからなる群から選択される少なくともひとつの化合物を含む、請求項14 に記載の使用。 16.前記IL-1レセプターアンタゴニストがヒトの組換えIL-1raである、請求 項15に記載の方法。 17.前記薬物中のIL-1インヒビターが約200mgまでの量で存在する、請求項 12〜16に記載の使用。 18.前記メトトレキセートが経口投与される、請求項13〜17に記載の使 用。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3279096P | 1996-12-06 | 1996-12-06 | |
US60/032,790 | 1996-12-06 | ||
US3635397P | 1997-01-23 | 1997-01-23 | |
US60/036,353 | 1997-01-23 | ||
US3931197P | 1997-02-07 | 1997-02-07 | |
US60/039,311 | 1997-02-07 | ||
US5202597P | 1997-07-09 | 1997-07-09 | |
US60/052,025 | 1997-07-09 | ||
PCT/US1997/022720 WO1998024477A1 (en) | 1996-12-06 | 1997-12-08 | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006209209A Division JP2006306890A (ja) | 1996-12-06 | 2006-07-31 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
JP2008222907A Division JP2009007380A (ja) | 1996-12-06 | 2008-08-29 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002509529A true JP2002509529A (ja) | 2002-03-26 |
JP4771563B2 JP4771563B2 (ja) | 2011-09-14 |
Family
ID=27488035
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52589298A Expired - Lifetime JP4771563B2 (ja) | 1996-12-06 | 1997-12-08 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
JP2006209209A Withdrawn JP2006306890A (ja) | 1996-12-06 | 2006-07-31 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
JP2008222907A Withdrawn JP2009007380A (ja) | 1996-12-06 | 2008-08-29 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006209209A Withdrawn JP2006306890A (ja) | 1996-12-06 | 2006-07-31 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
JP2008222907A Withdrawn JP2009007380A (ja) | 1996-12-06 | 2008-08-29 | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US20030072756A1 (ja) |
EP (2) | EP0949931B1 (ja) |
JP (3) | JP4771563B2 (ja) |
AT (1) | ATE406176T1 (ja) |
AU (1) | AU736876B2 (ja) |
CA (1) | CA2273852C (ja) |
DE (1) | DE69738948D1 (ja) |
ES (2) | ES2312179T3 (ja) |
HK (1) | HK1023501A1 (ja) |
WO (1) | WO1998024477A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006035876A1 (ja) * | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
WO2006104172A1 (ja) * | 2005-03-29 | 2006-10-05 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
WO2007026737A1 (ja) * | 2005-08-31 | 2007-03-08 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療法 |
WO2008001499A1 (fr) * | 2006-06-29 | 2008-01-03 | Kowa Co., Ltd. | Agent prophylactique et/ou thérapeutique pour le traitement de la polyarthrite rhumatoïde |
JP2009007380A (ja) * | 1996-12-06 | 2009-01-15 | Amgen | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
JP2014012703A (ja) * | 2009-08-27 | 2014-01-23 | Biomet Biologics Llc | インターロイキン−1受容体アンタゴニストを送達するための方法および組成物 |
US9701728B2 (en) | 2008-02-27 | 2017-07-11 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US10576130B2 (en) | 2013-03-15 | 2020-03-03 | Biomet Manufacturing, Llc | Treatment of collagen defects using protein solutions |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2422231T3 (es) | 1998-10-23 | 2013-09-09 | Kirin Amgen Inc | Péptidos miméticos de trombopoyetina diméricos que se unen al receptor MP1 y que tienen actividad trombopoyética |
WO2000056298A2 (en) * | 1999-03-19 | 2000-09-28 | Luitpold Pharmaceuticals, Inc. | Treatment of lyme disease with polysulfated glycosaminoglycan formulations |
CN101850120A (zh) * | 1999-07-21 | 2010-10-06 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
AU6376700A (en) * | 1999-07-28 | 2001-02-19 | Schering Corporation | Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
US6544504B1 (en) | 1999-07-28 | 2003-04-08 | Schering Corporation | Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
EP1095661A1 (en) * | 1999-11-01 | 2001-05-02 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Prevention and treatment of biomaterial-associated infections |
US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
AU2001259432B2 (en) * | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
DE10132308A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Kombinationspräparat zur Therapie von immunologischen Erkrankungen |
WO2003099808A1 (en) | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
AU2005311101B8 (en) * | 2004-12-02 | 2011-03-03 | Domantis Limited | Anti-IL-IRI single domain antibodies and therapeutic uses |
US20060160737A1 (en) * | 2005-01-14 | 2006-07-20 | Allen Radin | Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2007049732A1 (ja) * | 2005-10-28 | 2007-05-03 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療法 |
AU2006321367B2 (en) * | 2005-12-01 | 2011-11-03 | Domantis Limited | Competitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
US10105441B2 (en) * | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
CN102596246A (zh) * | 2009-08-20 | 2012-07-18 | Twi生物技术有限公司 | 诊断糖尿病及测定治疗疗效的方法 |
AU2010292486B2 (en) | 2009-08-27 | 2014-08-07 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
EP2598526B1 (en) | 2010-07-29 | 2018-09-05 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
WO2012078101A1 (en) * | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
RU2014107743A (ru) * | 2011-07-29 | 2015-09-10 | Илэвэн Байотерапьютикс, Инк. | Очищенные белки |
SG11201507447PA (en) | 2013-03-13 | 2015-10-29 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2512572A (en) | 1950-06-20 | Substituted pteridines and method | ||
US3989703A (en) | 1974-03-22 | 1976-11-02 | Institutul Oncologic | Process of preparing N[p-{[(2,4-diamino-6-pteridyl)-methyl]N10 -methylamino}-benzoyl]-glutamic acid |
US3892801A (en) | 1974-09-11 | 1975-07-01 | American Cyanamid Co | Method for preparing alkali salts of p-methylaminobenzoylglutamic acid |
US4079056A (en) | 1975-03-31 | 1978-03-14 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Method of making pteridine compounds |
US4057548A (en) | 1975-11-11 | 1977-11-08 | Jacek Wiecko | Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor |
US4067867A (en) | 1976-03-30 | 1978-01-10 | Jacek Wiecko | Process for preparing pyrazine precursor of methotrexate or an N-substituted derivative thereof and/or a di(lower)alkyl ester thereof |
US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
CH630380A5 (de) | 1977-08-12 | 1982-06-15 | Lonza Ag | Verfahren zur herstellung von l-methotrexat. |
US4136101A (en) | 1978-02-03 | 1979-01-23 | American Cyanamid Company | Process for preparing dialkyl (p-aminobenzoyl) glutamates |
US4306064A (en) | 1980-03-25 | 1981-12-15 | Ellard James A | Synthesis of 2,4-diamino-6-hydroxymethylpteridine |
US4421913A (en) | 1980-04-23 | 1983-12-20 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Separation of triphenylphosphine oxide from methotrexate ester and purification of said ester |
US4374987A (en) | 1980-08-14 | 1983-02-22 | American Cyanamid Company | Process for the preparation of high purity methotrexate and derivatives thereof |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4716224A (en) | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
SE442820B (sv) | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
US4863907A (en) | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4636524A (en) | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4605691A (en) | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
SE8501022L (sv) | 1985-03-01 | 1986-09-02 | Pharmacia Ab | Format alster och forfarande for dess framstellning |
US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
US5202431A (en) | 1985-07-08 | 1993-04-13 | Fidia, S.P.A. | Partial esters of hyaluronic acid |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
JPS6291197A (ja) | 1985-10-17 | 1987-04-25 | Dainippon Pharmaceut Co Ltd | 抗ヒトインタ−ロイキン1抗体,その製法及びその使用法 |
FR2590255B1 (fr) | 1985-11-19 | 1987-12-24 | Rhone Poulenc Sante | Procede de preparation de derives de la pteridine |
US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US5359032A (en) * | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
EP0364778B1 (en) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1beta |
FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
US4957774A (en) | 1988-12-14 | 1990-09-18 | Canon Kabushiki Kaisha | Method of heat-fixing toner image |
JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
US5041554A (en) * | 1989-01-31 | 1991-08-20 | Merrell Dow Pharmaceuticals Inc. | Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
CA2017025C (en) | 1989-05-18 | 2008-07-22 | David Wallach | Tumor necrosis factor binding protein ii, its purification and antibodies thereto |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5356883A (en) | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
EP0502956B1 (en) | 1989-11-29 | 1997-04-23 | Amgen Boulder Inc. | Production of recombinant human interleukin-1 inhibitor |
AU642938B2 (en) | 1989-12-13 | 1993-11-04 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1) |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
WO1991017249A1 (en) * | 1990-05-01 | 1991-11-14 | Cetus Corporation | Interleukin-1 antagonist and uses thereof |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
DE69114500T2 (de) | 1990-07-13 | 1996-06-13 | Transkaryotic Therapies Inc | Verfahren zum absuchen einer bibliothek. |
US5932537A (en) * | 1990-10-09 | 1999-08-03 | Chiron Corporation | Method for attenuating a cellular response to IL-1 |
US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
RU2166955C2 (ru) | 1991-01-18 | 2001-05-20 | Эмген Инк. | Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток |
ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
GR920100122A (el) | 1991-04-05 | 1993-03-16 | Ethicon Inc | Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως. |
EP0510691B1 (en) | 1991-04-26 | 2004-11-03 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
CA2114713A1 (en) | 1991-08-02 | 1993-02-18 | Douglas A. Treco | Library screening method |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
WO1993007863A1 (en) | 1991-10-15 | 1993-04-29 | Mullarkey Michael F | Methods and compositions for treating allergic reactions |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
CA2130762C (en) | 1994-08-24 | 1999-07-06 | Eva Anne Turley | Treatment of disease and conditions associated with macrophage infiltration |
EP0670730B1 (en) | 1992-03-30 | 2003-06-04 | Immunex Corporation | Fusion protein comprising two tumor necrosis factor receptors |
JPH07509223A (ja) | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
DE4219626A1 (de) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
JPH0630788A (ja) | 1992-07-16 | 1994-02-08 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−1に対する組換え抗体 |
CZ291261B6 (cs) | 1992-09-17 | 2003-01-15 | Amgen Inc. | Farmaceutická kompozice pro léčení nemocí zprostředkovaných interleukinem-1 |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
US5340572A (en) * | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
CA2157782A1 (en) | 1993-03-08 | 1994-09-15 | Joseph C. Glorioso | Gene transfer for treating a connective tissue of a mammalian host |
DK0689449T3 (da) | 1993-03-19 | 2003-03-03 | Vacsyn Sa | Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5508262A (en) * | 1993-12-15 | 1996-04-16 | University Of South Florida | Interleukin-1 receptor antagonist decreases severity of acute pancreatitis |
IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
IT1270662B (it) * | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
TW313568B (ja) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US5690961A (en) | 1994-12-22 | 1997-11-25 | Hercules Incorporated | Acidic polysaccharides crosslinked with polycarboxylic acids and their uses |
AU705281B2 (en) | 1994-12-23 | 1999-05-20 | Uab Research Foundation | Secreted human fas antigen |
US5723116A (en) * | 1995-01-06 | 1998-03-03 | University Of South Florida | Decreased mortality of severe acute pancreatitis following proximal cytokine blockade |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
EP0904112B1 (en) | 1996-02-09 | 2009-11-18 | Amgen Inc., | Composition comprising il-1ra as interleukin-1 inhibitor and hyaluronan as controlled release polymer |
US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
ES2312179T3 (es) * | 1996-12-06 | 2009-02-16 | Amgen Inc. | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. |
US5968607A (en) * | 1997-12-10 | 1999-10-19 | Chromium Graphics | Device and method for etch and emboss process printing |
-
1997
- 1997-12-08 ES ES97954087T patent/ES2312179T3/es not_active Expired - Lifetime
- 1997-12-08 EP EP97954087A patent/EP0949931B1/en not_active Expired - Lifetime
- 1997-12-08 WO PCT/US1997/022720 patent/WO1998024477A1/en active IP Right Grant
- 1997-12-08 DE DE69738948T patent/DE69738948D1/de not_active Expired - Lifetime
- 1997-12-08 ES ES08014990.9T patent/ES2615357T3/es not_active Expired - Lifetime
- 1997-12-08 CA CA002273852A patent/CA2273852C/en not_active Expired - Lifetime
- 1997-12-08 AU AU57955/98A patent/AU736876B2/en not_active Expired
- 1997-12-08 AT AT97954087T patent/ATE406176T1/de not_active IP Right Cessation
- 1997-12-08 EP EP08014990.9A patent/EP2002846B1/en not_active Expired - Lifetime
- 1997-12-08 JP JP52589298A patent/JP4771563B2/ja not_active Expired - Lifetime
-
2000
- 2000-04-18 HK HK00102322.5A patent/HK1023501A1/xx not_active IP Right Cessation
-
2002
- 2002-10-04 US US10/265,037 patent/US20030072756A1/en not_active Abandoned
-
2003
- 2003-07-16 US US10/621,784 patent/US20040044001A1/en not_active Abandoned
-
2006
- 2006-07-31 JP JP2006209209A patent/JP2006306890A/ja not_active Withdrawn
-
2008
- 2008-08-29 JP JP2008222907A patent/JP2009007380A/ja not_active Withdrawn
-
2009
- 2009-02-27 US US12/380,535 patent/US20090203609A1/en not_active Abandoned
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009007380A (ja) * | 1996-12-06 | 2009-01-15 | Amgen | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
WO2006035876A1 (ja) * | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
WO2006104172A1 (ja) * | 2005-03-29 | 2006-10-05 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
WO2007026737A1 (ja) * | 2005-08-31 | 2007-03-08 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療法 |
WO2008001499A1 (fr) * | 2006-06-29 | 2008-01-03 | Kowa Co., Ltd. | Agent prophylactique et/ou thérapeutique pour le traitement de la polyarthrite rhumatoïde |
US10106587B2 (en) | 2008-02-27 | 2018-10-23 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9308224B2 (en) | 2008-02-27 | 2016-04-12 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9701728B2 (en) | 2008-02-27 | 2017-07-11 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US11725031B2 (en) | 2008-02-27 | 2023-08-15 | Biomet Manufacturing, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US10400017B2 (en) | 2008-02-27 | 2019-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
JP2014012703A (ja) * | 2009-08-27 | 2014-01-23 | Biomet Biologics Llc | インターロイキン−1受容体アンタゴニストを送達するための方法および組成物 |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10441634B2 (en) | 2013-03-15 | 2019-10-15 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10576130B2 (en) | 2013-03-15 | 2020-03-03 | Biomet Manufacturing, Llc | Treatment of collagen defects using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US11957733B2 (en) | 2013-03-15 | 2024-04-16 | Biomet Manufacturing, Llc | Treatment of collagen defects using protein solutions |
Also Published As
Publication number | Publication date |
---|---|
US20040044001A1 (en) | 2004-03-04 |
EP0949931A1 (en) | 1999-10-20 |
WO1998024477A1 (en) | 1998-06-11 |
CA2273852A1 (en) | 1998-06-11 |
EP0949931B1 (en) | 2008-08-27 |
AU736876B2 (en) | 2001-08-02 |
ES2615357T3 (es) | 2017-06-06 |
EP2002846B1 (en) | 2017-01-25 |
JP2006306890A (ja) | 2006-11-09 |
EP2002846A3 (en) | 2009-01-14 |
CA2273852C (en) | 2009-09-29 |
DE69738948D1 (de) | 2008-10-09 |
HK1023501A1 (en) | 2000-09-15 |
ES2312179T3 (es) | 2009-02-16 |
US20030072756A1 (en) | 2003-04-17 |
JP4771563B2 (ja) | 2011-09-14 |
EP2002846A2 (en) | 2008-12-17 |
ATE406176T1 (de) | 2008-09-15 |
JP2009007380A (ja) | 2009-01-15 |
US20090203609A1 (en) | 2009-08-13 |
AU5795598A (en) | 1998-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4771563B2 (ja) | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 | |
US6306820B1 (en) | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | |
ES2288304T3 (es) | Receptores tipo i del factor de necrosis tumoral truncados y solubles. | |
JP4344404B2 (ja) | インターロイキン―1インヒビターおよび制御放出ポリマーを含む組成物 | |
US6294170B1 (en) | Composition and method for treating inflammatory diseases | |
KR19990082399A (ko) | 인터루킨-1 저해제 및 조절 방출 중합체를 함유하는 조성물 | |
AU771793B2 (en) | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | |
EP1352656A2 (en) | Combination therapy using a TNF binding protein for treating TNF-mediated diseases | |
MXPA99005224A (en) | Combination therapy using a tnf binding protein for treating tnf-mediated diseases | |
MXPA99005227A (en) | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases | |
AU5400701A (en) | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060427 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060731 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080829 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081016 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090402 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091001 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091013 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110524 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110621 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140701 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |